Parallax Volatility Advisers’s Amicus Therapeutics FOLD Stock Holding History

Parallax Volatility Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,900	Closed	-$48.1K	–	1647
2025 Q1	$48.1K	Hold	5,900	–	–	﹤0.01%	1398
2024 Q4	$55.6K	Buy	+5,900	New	+$61.3K	﹤0.01%	1776
2019 Q3	–	Sell	-125,000	Closed	-$1.56M	–	2693
2019 Q2	$1.56M	Buy	+125,000	New	+$1.59M	﹤0.01%	1124
2018 Q4	–	Sell	-33,100	Closed	-$400K	–	3225
2018 Q3	$400K	Buy	33,100 +8,100	+32%	+$113K	﹤0.01%	1488
2018 Q2	$391K	Sell	25,000 -245,000	-91%	-$3.7M	﹤0.01%	1313
2018 Q1	$4.06M	Sell	270,000 -10,000	-4%	-$152K	0.01%	578
2017 Q4	$4.03M	Hold	280,000	–	–	0.01%	679
2017 Q3	$4.22M	Buy	+280,000	New	+$3.7M	0.01%	614
2015 Q4	–	Sell	-100,000	Closed	-$1.4M	–	3192
2015 Q3	$1.4M	Buy	+100,000	New	+$1.57M	﹤0.01%	1169

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Parallax Volatility Advisers's FOLD Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 5,900 shares — an estimated $48.1K sold.

Parallax Volatility Advisers first reported a position in FOLD in Q3 2015 and held it in 11 quarters. The position peaked at $2M in Q3 2017. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

Parallax Volatility Advisers reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
Parallax Volatility Advisers sold 5,900 Amicus Therapeutics shares in Q2 2025, an estimated $48.1K.
Parallax Volatility Advisers first reported a position in Amicus Therapeutics in Q3 2015 and held it in 11 quarters.
Parallax Volatility Advisers's Amicus Therapeutics position peaked at $2M in Q3 2017.
272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.